Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of CYD Dengue Vaccine and Gardasil in Healthy Children
NCT02993757Phase 3Completed
- Sponsor
- Sanofi
- Start
- Dec 2016
- Primary completion
- May 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of CYD-TDV in dengue fever (2 arms), sponsored by Sanofi. Primary endpoints: Geometric Mean Titers (GMTs) Against Each Gardasil Vaccine Human Papillomavirus (HPV) Antigen and Geometric Mean Titers Against Each Parental Dengue Virus Serotype. Started Dec 2016; status: completed.
02
Drugs
CYD-TDV
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT02993757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02993757.